PFIZER INC (PFE) is held by 16 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions, 6 funds adding, and 9 funds trimming or exiting versus the previous quarter. 0 members of Congress reported 0 purchases vs 1 sale. Latest close $28.06 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Hillman Capital Management · Sound Shore · Torray Investment Partners LLC — 16 tracked funds hold PFE. See all holders.
0 members of Congress reported buying (0 purchases vs 1 sale). Politician trading
Arcos Dorados Holdings Inc. (ARCO) · REGIONS FINANCIAL CORP (RF) · AMGEN INC (AMGN) · BP PLC (BP) · ALLSTATE CORP (ALL) — stocks the same funds also hold. See all related stocks.
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +19.2% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
Tracked funds holding this stock, by quarter (2016Q3–2026Q1, 22 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.
| Institutions holding | 2,832 of 8,857 filers |
| Long-only filers among them | 2,823 |
| Change vs 2026 Q1 | -88 net · 1,835 entered · 1,923 exited |
| Shares reported, all filers | 3,778,604,587 |
| Reported value, all filers | $92.8B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $62.6B |
| Net income · FY2025 | $7.8B |
| Total assets · FY2025 | $208.2B |
| Shares outstanding | 5,699,673,589 |
| Market cap (at latest close) | $159.9B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 29, 2026.
| Shares short · Oct 15, 2026 | 137,816,093 |
| Share of shares outstanding | 2.42% |
| Days to cover | 4.47 |
Shares short at recent settlements — Jul 31, 2026: 161.5M · Aug 14, 2026: 149.3M · Aug 31, 2026: 151.5M · Sep 15, 2026: 155.2M · Sep 30, 2026: 150.2M · Oct 15, 2026: 137.8M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 29, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 25K · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 29, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| May 23, 2025 | Dolsten Mikael | Former Officer | 59,781 | $1.4M | May 23, 2025 | SEC filing |
| May 5, 2025 | Dolsten Mikael | Former Officer | 55,000 | $1.3M | May 5, 2025 | SEC filing |
| Sep 13, 2023 | Pao William | Former Chief Development Officer; EVP | 54,379 | $1.9M | Sep 13, 2023 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| May 1, 2026 | Vanguard Capital Management | SC 13G | 427,444,872 | 7.5% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
0 members of Congress reported buying (0 purchases vs 1 sale).
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Tuberville, Tommy | Senate | R | 0 | 1 | Jun 8, 2026 | $15,001 - 50,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
| Member who traded this stock | Sits on |
|---|---|
| Tuberville, Tommy | Senate Committee on Health, Education, Labor, and Pensions |
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 1,192 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (626), Trade (domestic/foreign) (453), Taxation/Internal Revenue Code (425).
Federal contracts: $31.9B in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $13.3B |
| FY2022 | $16.7B |
| FY2023 | $1.9B |
| FY2024 | $-28.5M |
| FY2025 | $1.4M |
| FY2026 | $-127.7K |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| W58P0522C0001 | Department of Defense | $12.5B | Nov 17, 2021 |
| W15QKN21C0012 | Department of Defense | $11.1B | Dec 22, 2020 |
| W58P0521C0002 | Agency for International Development | $4.2B | Jul 30, 2021 |
| W58P0522C0016 | Department of Defense | $4.0B | Jun 29, 2022 |
| HHSD200201458152C | Department of Health and Human Services | $1.0B | Apr 1, 2014 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Insiders
· Opportunistic Buys (Non-Routine) — Last 90 days: 2 or more insiders with no routine buying pattern bought on the open market
Financial Screens
· Dividend Growth — Dividends raised for more than 10 years
· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Shareholder Yield — Cash returned through dividends and buybacks
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
Key figures
· Dividend Growth — Dividend per share: 1.72 · Dividend yield: 5.7% · Straight dividend years: 16 · 10-yr dividend growth: 41.0%
· Cash Flow (FCF) — Latest FCF: $9.1B · FCF yield: 5.3% · Positive FCF years: 3
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 2.40 · Operating cash flow: $11.7B · Net income: $7.8B
· Shareholder Yield — Shareholder yield: 5.7% · of which dividends: 5.7% · of which buybacks: 0.0%
· Opportunistic Buys (Non-Routine) — Opportunistic buyers: 3 · Buy txns: 3 · Buy value: $3.0M · Latest buy: Aug 12, 2026
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Super-investor 13F BEST — appeared in 22 of the last 40 quarterly lists; latest 2026 Q1, ranked #49 of 50.
· Politician BEST — appeared in 9 of the last 20 quarterly lists; latest 2025 Q2, ranked #40 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 9 | 66.7% | +0.2% | +0.4% | -0.2% |
| Share count tripled (3x) | 1 | 100.0% | +1.5% | +3.7% | -2.2% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold PFE — ranked by lift, the co-holding pattern described in Methodology: Arcos Dorados Holdings Inc. (ARCO) · REGIONS FINANCIAL CORP (RF) · AMGEN INC (AMGN) · BP PLC (BP) · ALLSTATE CORP (ALL) · CAMPBELL'S Co (CPB) · ING GROEP NV (ING) · TARGET CORP (TGT).
Filings audit: every filing lens on PFIZER INC (PFE), scored — GetCoattail Research.
| Filed | Items | Source |
|---|---|---|
| Nov 3, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 9.01 Financial Statements and Exhibits | SEC filing |
| Nov 3, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 4, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Arcos Dorados Holdings Inc. (ARCO) · Filings audit: every filing lens on PFIZER INC (PFE), scored · Practice timing on PFE
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.